Launch of Phase 3 clinical trial with Nefecon in Japan
The clinical trial is a bridging study requiring a limited number of Japanese patients to participate in a study similar in design to that of the global NefIgArd trial. IgA nephropathy is a designated retractable disease in
*
CONTACT:
Åsa Hillsten, Head of IR & Sustainability, Calliditas
Tel.: +46 76 403 35 43, Email: asa.hillsten@calliditas.com
The information was sent for publication, through the agency of the contact persons set out above, on
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
Viatris Trial Launch PR_ENG |
View original content:https://www.prnewswire.co.uk/news-releases/launch-of-phase-3-clinical-trial-with-nefecon-in-japan-302189479.html
![](https://rt.prnewswire.com/rt.gif?NewsItemId=EN54771&Transmission_Id=202407040344PR_NEWS_EURO_ND__EN54771&DateId=20240704)